Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications.
暂无分享,去创建一个
[1] L. Skov,et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] J. L. Abraham,et al. Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of gadolinium deposits in skin. , 2007, Journal of electron microscopy.
[3] A. Djamali,et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.
[4] E. Kanal,et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. , 2007, Radiology.
[5] S. Cowper,et al. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[6] W. C. O'Neill. Vascular calcification: not so crystal clear. , 2007, Kidney international.
[7] Gerald A Kirk,et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.
[8] J. Zic,et al. Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.
[9] S. Cowper,et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.
[10] M. Port,et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.
[11] Lone Skov,et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.
[12] G. Spasovski,et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] Sophie Laurent,et al. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. , 2006, Contrast media & molecular imaging.
[14] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] S. Cowper,et al. Nephrogenic systemic fibrosis: An update , 2006, Current rheumatology reports.
[16] M. Tweedle,et al. Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.
[17] R. Bucala,et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. , 2006, Seminars in arthritis and rheumatism.
[18] T. Ishiguchi,et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. , 2005, Radiation medicine.
[19] P. Leboit,et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.
[20] S. Hirano,et al. Exposure, metabolism, and toxicity of rare earths and related compounds. , 1996, Environmental health perspectives.
[21] J. Hagan,et al. Reaction of gadolinium chelates with endogenously available ions. , 1991, Magnetic resonance imaging.
[22] M. Markowitz,et al. Immobilization-related lead toxicity in previously lead-poisoned children. , 1990, Pediatrics.
[23] C. Evans. Biochemistry of the Lanthanides , 1990, Biochemistry of the Elements.
[24] W. Cacheris,et al. The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.
[25] J. Hagan,et al. Comparative chemical structure and pharmacokinetics of MRI contrast agents. , 1988 .
[26] V. Runge. Gd-DTPA: an i.v. contrast agent for clinical MRI. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.